Targeting the purinergic P2X7 receptor in epilepsy: Cell types matter

Area of Science:

• Neuroscience
• Pharmacology
• Immunology

Background:

• Epilepsy affects 70 million globally, posing a significant healthcare challenge.
• Current anti-seizure medications (ASMs) often fail due to drug refractoriness and side effects.
• Purinergic signaling via extracellular ATP, particularly through P2X7R, is implicated in epilepsy pathogenesis.

Purpose of the Study:

• To critically review the multifaceted role of P2X7 receptors in epilepsy.
• To emphasize the cell type-specific functions of P2X7R signaling in hyperexcitability and seizures.
• To explore the potential of P2X7R as a therapeutic target for epilepsy.

Main Methods:

• Literature review of studies investigating P2X7R in epilepsy models and human studies.
• Analysis of evidence linking P2X7R to inflammation, seizures, and drug resistance.
• Discussion of emerging research on cell-specific P2X7R functions.

Main Results:

• P2X7R antagonism shows promise in modulating acute seizures and reducing seizure burden.
• P2X7R's role in inflammation, particularly on microglia, is well-documented and linked to seizure severity.
• Emerging evidence suggests P2X7R signaling has context-dependent, cell-specific effects, including both pro- and anticonvulsive roles.

Conclusions:

• The role of P2X7R in epilepsy is more complex than solely inflammatory, involving cell-specific mechanisms.
• Targeting P2X7R offers potential for novel epilepsy therapies, but requires careful consideration of its diverse functions.
• Further research into cell type-specific P2X7R contributions is crucial for therapeutic development.